Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Nov 10.
Published in final edited form as: J Org Chem. 2012 Apr 13;77(9):4235–4241. doi: 10.1021/jo2026228

A Piperidine Chiron for the Veratrum Alkaloids

Douglass F Taber 1,*, Peter W DeMatteo 1
PMCID: PMC4226469  NIHMSID: NIHMS363522  PMID: 22401662

Abstract

graphic file with name nihms363522f8.jpg

A Veratrum piperidine chiron was prepared over 11 steps (7.9% yield) from (−)-citronellal. Three methods for the installation of the propargylic sidechain onto a cyclic enamide are presented.

Introduction

Veratramine (1) is an alkaloid isolated from plants of the genus Veratrum.1 This class of alkaloids also includes (Fig. 1) cyclopamine (2) and germine (3). The hedgehog pathway, which is blocked by cyclopamine, has come to prominence as a potential chemotherapeutic target over the course of the last decade for the treatment of inoperable cancers such as basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma.2

Figure 1.

Figure 1

Three representative Veratrum alkaloids.

A semi-synthetic derivative of cyclopamine 2, IPI-926 4 (Eq 1) is currently3 in Phase 2 clinical trials for pancreatic cancer. As natural supplies of Veratrum alkaloids are limited, modern synthetic approaches towards them are being pursued.4,5 As part of our research towards a convergent total synthesis of (−)-veratramine 1, we have prepared the Veratrum piperidine chiron 7 (Scheme 1) from commercial (−)-citronellal 5.

graphic file with name nihms363522f9.jpg (1)

Scheme 1.

Scheme 1

Results and Discussion

The starting point for the synthesis was the protected (−)-norcitronellamine 9 (Scheme 2). While this could be synthesized by our previously-reported method,6 the one-carbon degradation of (−)-citronelllic acid was more readily scalable.

Scheme 2.

Scheme 2

The first step was the oxidation of commercial (−)-citronellal to (−)-citronellic acid. The gram-scale Tollens oxidation introduced by Paquette7 proved particularly efficient. It was convenient to recycle the stoichiometric silver residues produced in the oxidation by digestion with concentrated nitric acid.

Carbamate inversion of the acid was accomplished via a mixed anhydride approach.8 Ozonolysis of (−)-N-tosyl norcitronellamine 9 proceeded, after filtration through silica gel, directly to the enesulfonamide 6.

Exposure of 6 (Scheme 3) to N-bromosuccinimide at low temperatures delivered the crystalline bromohydrin 10 as a single dominant diastereomer. Potassium hydride in paraffin [KH(P)]9 was used to generate the epoxide in situ. Addition of commercial 2-butenylmagnesium chloride then delivered a separable 1:1 mixture of the two crystalline diastereomers 13 and 14, the relative configurations of which were established by X-ray crystallography. Sequential benzylation10 and conversion to the alkyne11 completed the preparation of the Veratrum chiron 7 (11 steps, 7.9% overall yield from commercial (−)-citronellal).

Scheme 3.

Scheme 3

In order to access a complementary 2,5-cis piperidine scaffold, Lewis acid-mediated homologation was attempted on the bromohydrin 10 (Scheme 4). Such additions are known for cyclic hemiacetals12 and hemiaminals,13 but none had been reported utilizing the Marshall reagent, (M/P)-1-tributylstannyl-1,2-butadiene 16,14 a propargylic methyl chiron that heretofore has only been applied to polyketide synthesis.15 Reaction of bromohydrin 10 with the P-allene gave adduct 17 as the only diastereomer detected, while reaction with the M-allene gave adduct 18. The structures were unambiguously established by X-ray crystallography. The facial selectivity of the addition was controlled by the adjacent bromine, while the absolute configuration at the propargylic position was defined by the enantiomer of allene used. These readily-prepared piperidines might well be useful for the preparation of other alkaloids, such as (−)-deoxynupharidine.16

Scheme 4.

Scheme 4

In an attempt to prepare 7 via the Lewis-acid/allene approach, the bromohydrin 10 (Scheme 5) and the M-allene were combined and exposed sequentially to KH(P), to convert 10 into the corresponding epoxide, and then to BF3˙OEt2. The result was a complicated mixture that contained no detectable traces of debenzylated 7 by 1H NMR. The prolinol 19, also characterized by X-ray crystallography, was the only product identified from the reaction. Apparently, exposure of the intermediate epoxide to Lewis acid effected rearrangement to the aldehyde, to which the allene then added. While there were superficial differences between isomers 13 and 19 by 1H NMR, the 13C NMR spectra showed the aminated methylene resonance at δ > 50 for piperidine 13 and at δ < 50 for pyrrolidine 19.

Scheme 5.

Scheme 5

Recently, Giannis described the preparation of the lactone 245b (Scheme 6). We used the approach outlined above to prepare 24, then investigated its methylation. While we did not optimize this conversion, we did observe that 25, the only diastereomer detected, had the same relative and absolute configuration (X-ray) as 7.

Scheme 6.

Scheme 6

Conclusion

Two approaches toward the preparation of the Veratrum chiron 7 have been established. The flexibility of bromohydrins 10 and 22 and their in situ derived epoxides under cationic and anionic conditions have been demonstrated. We have also shown that addition of (M/P)-1-tributylstannyl-1,2-butadiene to the bromohydrin 10 delivered predictable and complementary diastereomers. Further application of 7 in the total synthesis of (−)-veratramine will be reported in due course.

Experimental Section

General Procedures

1H NMR and 13C NMR spectra were recorded, as solutions in deuteriochloroform (CDCl3) unless otherwise indicated, at 400 and 100 MHz, respectively. 13C multiplicities were determined with the aid of a JVERT pulse sequence, differentiating the signals for methyl and methine carbons as “down” from methylene and quaternary carbons as “up”. Rf values indicated refer to thin-layer chromatography (TLC) on 2.5 × 10 cm, 250 µm analytical plates coated with silica gel GF, and developed in the solvent system indicated. All glassware was rinsed with dry solvent before use. THF and diethyl ether were distilled from sodium metal/benzophenone ketyl under dry nitrogen. Toluene and dichloromethane were distilled from calcium hydride under dry nitrogen. MTBE is methyl-tert-butyl ether, and PE is petroleum ether. All reactions were conducted under N2 and stirred magnetically unless otherwise noted.

Revised Tollens Procedure / Procedure for Recycling Ag0/Ag2O Solids / Preparation of (−)-Citronellic acid (7)

The combined solids from a previous Tollens oxidation (105 g) were washed with 3 × 100 mL hot water and 1 × 100 mL acetone. The solids were then vacuum filtered to dryness. The solids were transferred to a 3-neck 2 L flask fitted with a mechanical stirrer and air inlet. The filter funnel was then rinsed with cHNO3 into the 3-neck flask. Minimum water was added to slurry the black solids and cHNO3 was added dropwise with evolution of reddish-brown gas. Acid addition was continued with stirring until no more black precipitate remained and gas evolution ceased, as evidenced by no color in the reaction headspace (c.a. 85 mL cHNO3, 1.35 mol). The solution was then filtered to remove solids, giving a pale yellow HNO3/AgNO3 solution, suitable for incorporation into the next Tollens oxidation. The solution was diluted to 250 mL and returned to the 3-neck flask. At this point one can follow the procedure put forth by Paquette et al., which is included here for convenience.8 Aqueous NaOH solution (250 mL, 5M) was added dropwise to the AgNO3 solution with vigorous stirring. The pH = 14 at about 75% addition of the NaOH solution. The remainder of the NaOH solution was added and the slurry was let age approximately 30 minutes. (−)-Citronellal (21.73 g, 140 mmol) was added in one portion and rinsed down with petroleum ether (~25 mL). The suspension was let stir overnight under air. In the morning a silver mirror was observed on the glassware and GC analysis of an acidified aliquot indicated complete conversion of the aldehyde. The foamy black suspension was then vacuum filtered with 3 × 100 mL rinses of hot water to give ~ 1L aqueous carboxylate solution that was then acidified with 25 mL cHCl. The system was then extracted with 3 × 250 mL of EtOAc and the combined organic extracts were dried (Na2SO4) and concentrated to leave citronellic acid (23.73 g, 139 mmol, 99%). The 3S-citronellic acid so prepared could be used without further purification.

(S)-N-(2,6-Dimethylhept-5-enyl)-4-toluenesulfonamide (9)

To (−)-citronellic acid 8 (8.00 g, 47 mmol) in 240 mL anhydrous acetone was added triethylamine (8.0 mL, 57.5 mmol). The solution was cooled to 0°C. Ethyl chloroformate (8.00 g, 73.7 mmol) was then added with vigorous stirring causing a white precipitate to form instantaneously. After 60 minutes, sodium azide (8.0 g, 123 mmol dissolved in 60 mL H2O) was added and the biphasic mixture was stirred for another hour. H2O (200 mL) was then added and the organic phase partitioned. The aqueous phase was extracted with another 3 × 125 mL EtOAc. The combined organic extracts were then partitioned against 100 mL of brine and dried with Na2SO4. After decantation, benzyl alcohol (16 mL, 154 mmol), 4Å molecular sieve (10.00 g), and toluene (50 mL) were added and the solution was subjected to atmospheric pressure short-path distillation which was halted when the head temperature reached 110°C. The bottoms were then taken up with 3 × 50 mL EtOAc. The solution was filtered, and the filtrate was concentrated. The residue was subjected to bulb-to-bulb distillation (pot = 100°C, 2 mm Hg) to ensure complete removal of the toluene and residual benzyl alcohol.

Diethyl ether (300 mL) was then used to dissolve the pot residue (under N2), and 300 mL of anhydrous NH3 was condensed into the system. Li metal (high Na, 3.0 g) was then added until a deep blue color persisted for 5 min, indicating complete reduction of the benzylic position. The solution was then allowed to come to RT, and 300 mL of H2O was added to dissolve the remaining solids. The biphasic solution was acidified to pH=5 with concentrated HCl and then rendered alkaline to pH=11 with solid sodium bicarbonate (foams!). p-Toluenesulfonyl chloride (9.5 g, 50 mmol) was then added with an equimolar amount of NaHCO3 (3.7 g, 50 mmol) and 100 mL of ethyl acetate, and the solution was allowed to stir overnight. The mixture was extracted with ethyl acetate (3 × 100 mL). The combined organic extract was dried (Na2SO4) and concentrated, and the residue was chromatographed to yield 9 as an oil that solidified on standing (11.12 g, 37.6 mmol, 80% yield from 5).

TLC Rf = 0.20 (10% EtOAc/PE); [α]D20=5.48 (c=0.157 CHCl3); 1 H NMR (400 MHz, CDCl3) δ ppm 0.86 (d, J=6.7 Hz, 3 H), 1.04 – 1.16 (m, 1 H), 1.27 – 1.39 (m, 1 H), 1.49 – 1.70 (m, 7 H), 1.90 (td, J=15.8, 7.3 Hz, 2 H), 2.42 (s, 3 H), 2.66 – 2.93 (m, 2 H), 4.94 – 5.08 (m, 2 H), 7.27 – 7.32 (d, J=7.2 Hz, 2 H), 7.74 – 7.79 (d, J=7.2 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 143.2, 136.8, 131.7, 48.9, 33.9, 25.0 (down) 129.6, 127.0, 123.9, 32.5, 25.6, 21.5, 17.5, 17.2; IR (film) 3283, 2963.3, 2924, 1452, 1325, 1150 cm−1; HRMS calcd for C16H25NO2NaS 318.1504, obsd 318.1510.

(S)-3-Methyl-1-tosyl-1,2,3,4-tetrahydropyridine (6)

The sulfonamide 9 (3.0 g, 10 mmol) was taken up in 100 mL of CH2Cl2. Sudan III (10 mg) was added as an indicator. The solution was cooled to −78°C and ozone was bubbled through until the red color faded. Methyl sulfide (1.0 mL, 13.5 mmol) was then added to reduce the ozonide. The solution was evaporated to silica gel and directly chromatographed to give 6 as an off-white solid (1.6 g, 6.5 mmol, 65% yield from 9); mp = 83–85°C; TLC Rf = 0.36 (10% EtOAc/PE); [α]D18=3.6 (c= 0.02 CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 0.91 (d, J=6.7 Hz, 3 H), 1.54 (dd, J=17.4, 9.3 Hz, 1 H), 1.71 – 1.82 (m, 1 H) 1.94 – 2.04 (m, 1 H) 2.42 (s, 3 H) 2.64 (t, J=10.8 Hz, 1 H) 3.59 (d, J=11.7 Hz, 1 H) 4.89 – 4.96 (m, 1 H) 6.63 (d, J=8.1 Hz, 1 H) 7.31 (d, J=7.9 Hz, 2 H) 7.66 (d, J=7.9 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 143.5, 135.1, 49.8, 29.3; (down) 129.7, 127.0, 124.5, 107.3, 26.4, 21.5, 18.6. IR (film) 3062, 2950.0, 2922, 1649, 1598, 1458, 1347, 1257 cm−1; HRMS calcd for C13H17NO2NaS 274.0878, obsd 274.0886.

(2R, 3S, 5S)-3-Bromo-5-methyl-1-tosylpiperidin-2-ol (10)

The ene sulfonamide 6 (1.30 g, 5.3 mmol) was dissolved in 100 mL of 95% acetone/water at rt. Ammonium acetate (100 mg, 1.3 mmol) was added as a catalyst. The solution was cooled to −78°C and N-bromosuccinimide (1.15 g, 6.4 mmol) was added in one portion. The yellow mixture was allowed to warm to rt over 3 h. Sodium bisulfite (1.0 g, 10 mmol) was then added and the acetone was removed via rotary evaporation. Water (20 mL) was added to dissolve solids and the resulting biphasic solution was extracted with CH2Cl2 (3 × 50 mL). The combined organic extract was dried (Na2SO4) and evaporated directly to silica gel for chromatography to give the bromohydrin 10 (1.206 g, 3.6 mmol, 70% yield from 6). mp = 100–102°C, crystals from EtOAc/heptanes; TLC Rf = 0.64 (25% EtOAc/PE); [α]D20=7.14 (c=0.11 CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 0.93 (d, J=6.8 Hz, 3 H) 1.84 – 2.02 (m, 2 H) 2.17 (dt, J=6.8, 4.5 Hz, 1 H) 2.44 (s, 3 H) 2.80 – 2.92 (m, 2 H) 3.46 (dd, J=11.6, 4.3 Hz, 1 H) 4.29 (q, J=2.8 Hz, 1 H) 5.56 (t, J=2.8 Hz, 1 H) 7.29 – 7.36 (m, 2 H) 7.78 – 7.85 (m, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 143.9, 136.1, 45.7, 34.0; (down) 129.6, 127.6, 78.9, 48.9, 25.2, 21.5, 18.1; IR (film) 3473, 2958, 2876, 1598, 1458, 1334, 1162 cm−1; HRMS calcd for C13H18NO3NaSBr 370.0088, obsd 370.0078.

(2S, 3R, 5S)-2-((R/S)-But-3-en-2-yl)-5-methyl-1-tosylpiperidin-3-ol (13/14)

KH(P) (480 mg, 6.0 mmol) was suspended in 10 mL toluene and brought to 60°C with stirring. Stirring was stopped and the KH precipitated. Approximately 9 mL of toluene was then removed from the reactor as it cooled to RT. CH2Cl2 (3.0 mL) was added and stirring was resumed. The bromohydrin 9 (694 mg, 2 mmol) was added dropwise as a solution in 5.0 mL CH2Cl2 over 5 min. The opaque yellow solution was stirred for an additional 30 min. Commercial 2-butenylmagnesium chloride (6.0 mL, 0.5 M in THF) was diluted with an equal portion of THF and cooled to −78°C. The cyclized bromohydrin mixture was added dropwise to the Grignard solution with stirring. Upon completion of addition, the cooling bath was removed and the reaction was allowed to come to rt over 45 min. The reaction was quenched with 10 mL of saturated aqueous NH4Cl. The aqueous layer was separated and extracted with 3 × 10 mL methylene chloride. The combined organic extracts were dried (Na2SO4) and chromatographed to give 210 mg of diastereomer 13 and 210 mg of diastereomer 14 in 65% total yield from the starting bromohydrin.

Front diastereomer - (2S,3R,5S)-2-((R)-but-3-en-2-yl)-5-methyl-1-tosylpiperidin-3-ol (13): TLC Rf = 0.40 (30% EtOAc/PE); [α]D19=19.6 (c=0.01 CHCl3); mp = 103–104°C; 1H NMR (400 MHz, CDCl3) δ ppm 0.81 (d, J=6.8 Hz, 3 H) 0.93 (d, J=7.1 Hz, 3 H) 1.31 – 1.43 (m, 1 H) 1.75 – 1.91 (m, 2 H) 1.99 (d, J=6.1 Hz, 1 H) 2.31 – 2.46 (m, 4 H) 3.21 (dd, J=13.6, 4.3 Hz, 1 H) 3.40 – 3.52 (m, 1 H) 3.66 (d, J=10.9 Hz, 1 H) 3.92 (m, 1 H) 4.95 – 5.08 (m, 2 H) 5.64 (ddd, J=17.0, 10.0, 9.1 Hz, 1 H) 7.26 – 7.30 (d, J=8.3 Hz, 2 H) 7.76 (d, J=8.3 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 143.1, 137.9, 115.8, 45.5, 32.0; (down) 140.9, 129.4, 127.5, 66.7, 63.5, 39.1, 26.0, 21.5, 20.7, 18.1; IR (film) 3524, 2928, 1598, 1456, 1324, 1152 cm−1 ; HRMS calcd for C17H25NO3NaS 346.1447, obsd 346.1448.

Back diastereomer - (2S,3R,5S)-2-((S)-but-3-en-2-yl)-5-methyl-1-tosylpiperidin-3-ol (14): TLC Rf = 0.27 (30% EtOAc/PE); [α]D19=34.6 (c=0.01 CHCl3); mp = 107–108°C; 1H NMR (400 MHz, CDCl3) δ ppm 1.04 (m, 7 H) 1.41 – 1.51 (m, 1 H) 1.78 – 1.95 (m, 2 H) 2.25 (d, J=6.6 Hz, 1 H) 2.35 – 2.47 (m, 4 H) 3.23 (m, 1 H) 3.51 (m, 1 H) 3.64 (d, J=10.4 Hz, 1 H) 3.92 (m, 1 H) 4.71 (dd, J=10.1, 1.5 Hz, 1 H) 4.92 (dd, J=17.2, 1.5 Hz, 1 H) 5.23 (m, 1 H) 7.26 – 7.33 (d, J=8.3 Hz, 2 H) 7.73 (d, J=8.3 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 143.0, 138.0, 114.5, 45.9, 32.7; (down) 140.5, 129.3, 127.6, 66.5, 64.1, 39.1, 26.0, 21.5, 20.8, 18.6; IR (film) 3520, 2929, 1598, 1458, 1325, 1150 cm−1 ; HRMS calcd for C17H25NO3NaS 346.1447, obsd 346.1445.

(2S,3R,5S)-3-Benzyloxy-2-((S)-but-3-en-2-yl)-5-methyl-1-tosylpiperidine (15)

KH(P) (160 mg, 2 mmol) was suspended in 10 mL toluene and brought to 60°C with stirring. Stirring was ceased and the KH precipitated. Approximately 9 mL of toluene was then removed from the reactor as it cooled to rt. Benzyl bromide (1 mL) was then added and the suspension was then re-heated to 60°C. The alcohol 13 (210 mg, 0.65 mmol) in 5.0 mL THF was added dropwise to the KH suspension over 5 min. After 3h, the mixture was quenched with 10 mL of H2O, then extracted with 3 × 10 mL CH2Cl2. The combined organic extracts were dried (Na2SO4) and chromatographed to give 15 (256 mg, 0.60 mmol, 95%) as a colorless oil; TLC Rf = 0.52; (15% EtOAc/PE); [α]D19=73.8 (c=0.01 CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 0.67 (d, J=7.0 Hz, 3 H) 1.08 (d, J=6.6 Hz, 3 H) 1.34 – 1.45 (m, 1 H) 1.69 – 1.86 (m, 2 H) 2.31 (s, 3 H) 2.36 – 2.49 (m, 1 H) 3.08 – 3.28 (m, 2 H) 3.53 – 3.62 (m, 1 H) 4.08 (d, J=10.1 Hz, 1 H) 4.36 – 4.54 (m, 2 H) 4.98 – 5.07 (m, 2 H) 5.93 (m, 1 H) 6.97 (d, J=8.2 Hz, 2 H) 7.22 – 7.42 (m, 5 H) 7.66 (d, J=8.2 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 142.2, 138.3, 138.2, 114.7, 70.1, 46.1, 29.6; (down) 141.0, 128.8, 128.2, 127.7, 127.5, 127.4, 73.6, 61.3, 39.6, 26.0, 21.4, 20.0, 18.8; IR (film) 2927, 1716, 1599, 1456, 1330, 1152 cm−1; HRMS calcd for C24H31NO3NaS 436.1966, obsd 436.1961.

(2S,3R,5S)-3-Benzyloxy-2-((S)-but-3-yn-2-yl)-5-methyl-1-tosylpiperidine (7)

Olefin 15 (256 mg, 0.60 mmol) and methanesulfonamide (95 mg, 1 mmol) were combined with 5 mL of t-BuOH and 5 mL of H2O with good stirring. After dissolution, the solution was cooled to 0°C and 1.4 g AD-mix α was added. After a week of stirring at room temperature, TLC indicated complete consumption of the olefin. NaHSO3 (0.5 g, 5 mmol) was added along with 10 mL of CH2Cl2and the suspension was stirred for 1 h. The suspension was then extracted with 3 × 20 mL CH2Cl2 and the combined organic phases were concentrated.

The residue was taken up in 10 mL of Et2O, 10 mL of H2O, and 3 mL of saturated aqueous NaHCO3. The biphasic mixture was cooled to 0°C and NaIO4 (426 mg, 2.0 mmol) was added in one portion. After 6 h, the reaction was extracted with 3 × 20 mL Et2O. The combined organic extracts were dried (Na2SO4) and chromatographed to give the intermediate aldehyde which was not characterized, as well as 116 mg of recovered diols, that was recycled into recycled into subsequent cleavage reactions. For the 15-diols mixture: 1H NMR (400 MHz, CDCl3) δ 0.66 – 0.75 (m, 3 H), 0.95 (d, J=7.1 Hz, 3 H), 1.74 – 1.88 (m, 2 H), 2.08 – 2.17 (m, 1 H), 2.27 – 2.38 (m, 3 H), 3.08 – 3.18 (m, 1 H), 3.47 (dd, J=13.5, 4.9 Hz, 1 H), 3.56 (dd, J=12.0, 8.5 Hz, 1 H), 3.63 – 3.70 (m, 1 H), 3.90 – 3.98 (m, 1 H), 4.07 – 4.13 (m, 1 H), 4.41 (d, J=1.5 Hz, 2 H), 6.93 – 7.05 (d, J=8.1 Hz, 2 H), 7.19 – 7.28 (m, 2 H), 7.31 – 7.42 (m, 3 H), 7.65 – 7.74 (m, 2 H).

The crude aldehyde was dissolved in 5 mL THF and added immediately to an aged solution (15 min) of TMS diazomethane (1.0 mL of 2.0 M) and nBuLi (0.75 mL of 2.5 M) in 3 mL THF at −78°C. The cooling bath was removed. After 30 min, the mixture was quenched with 10 mL of saturated aqueous NH4Cl. The mixture was extracted with 3 × 20 mL CH2Cl2. The combined organic extracts were dried (Na2SO4) and chromatographed to give the alkyne (100 mg, 0.24 mmol, 40% yield from 15 (70% based on recovered diols)); TLC Rf = 0.50 (15% EtOAc/PE); [α]D19=53.5 (c=0.01 CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 0.72 (d, J=6.9 Hz, 3 H), 1.22 – 1.29 (m, 1 H), 1.32 (d, J=7.0 Hz, 3 H), 1.77 – 1.90 (m, 2 H), 2.12 (d, J=2.6 Hz, 1 H), 2.34 (s, 3 H), 2.84 (m, 1 H), 3.15 (dd, J=13.4, 5.2 Hz, 1 H), 3.54 (dd, J=13.4, 5.2 Hz, 1 H), 3.61 (td, J=4.7, 2.3 Hz, 1 H), 4.17 (dd, J=7.5, 2.3 Hz, 1 H), 4.39 – 4.52 (m, 2 H), 7.24 – 7.38 (m, 5 H), 7.65 – 7.77 (m, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 142.6, 138.2, 137.7, 85.4, 71.5, 70.2, 46.7, 30.4; (down) 129.0, 128.3, 127.8, 127.5, 127.5, 74.6, 60.7, 29.0, 26.0, 21.5, 20.2, 18.8; IR (film) 3302, 3032, 2931, 2254, 1810, 1731, 1599, 1496, 1456, 1331 cm−1; HRMS calcd for C24H29NO3NaS 434.1760, obsd 434.1759.

(2R, 3S, 5S)-3-Bromo-2-((R)-but-3-yn-2-yl)-5-methyl-1-tosylpiperidine (17)

Bromohydrin 10 (0.549 g, 1.64 mmol) and P-Marshall reagent 16 (600 mg, 1.74 mmol) were dissolved in 16 mL of CH2Cl2 at RT. The solution was cooled to −78°C and BF3˙OEt2 (250 µL, 1.92 mmol) was added in one portion. TLC indicated reaction completion in 30 minutes. Saturated aqueous NaHCO3 (1 mL) along with 1 mL of saturated aqueous KF were added and the reaction was allowed to come to rt. Precipitates were filtered and the resulting biphasic solution was extracted with methylene chloride (3 × 25 mL). The combined organic fractions were dried (Na2SO4) and evaporated to silica gel for chromatography to give 17 as a white crystalline solid (338 mg, 0.88 mmol, 54%); TLC Rf = 0.34 (15% EtOAc/PE); [α]D18=13.6 (c=0.07 CHCl3); mp = 153–155°C; 1H NMR (400 MHz, CDCl3) δ ppm 0.84 (d, J=6.1 Hz, 3 H), 1.37 (d, J=6.9 Hz, 3 H), 1.82 – 2.03 (m, 3 H), 2.12 (d, J=2.5 Hz, 1 H), 2.42 (s, 3 H), 2.82 – 3.02 (m, 2 H), 3.59 (dd, J=14.3, 4.1 Hz, 1 H), 4.37 (d, J=7.8 Hz, 1 H), 4.49 (d, J=1.8 Hz, 1 H), 7.20 – 7.39 (m, 3 H), 7.87 (d, J=8.3 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 142.9, 137.9, 84.97, 72.6, 47.6, 36.8; (down) 129.1, 128.0, 62.9, 48.9, 39.2, 24.4, 21.5, 19.6, 18.1.; IR (film) 2954, 2871, 1737, 1453, 1336, 1169 cm−1; HRMS calcd for C17H23NO2SBr 384.0633, obsd 384.0630.

(2R,3S,5S)-3-bromo-2-((S)-but-3-yn-2-yl)-5-methyl-1-tosylpiperidine (18)

Bromohydrin 10 (0.247 g, 0.74 mmol) and M-Marshall reagent 16 (330 mg, 1.0 mmol) were dissolved in 10 mL of CH2Cl2 at RT. The solution was cooled to −78°C and BF3˙OEt2 (125 µL, 1.0 mmol) was added in one portion. TLC indicated that the reaction was complete in 30 min. Saturated aqueous NaHCO3 (1 mL) along with 1 mL of saturated aqueous KF were added and the reaction was allowed to come to rt. Precipitates were filtered and the resulting biphasic solution was extracted with methylene chloride (3 × 25 mL). The combined organic fractions were dried (Na2SO4) and evaporated to silica gel for chromatography to give 18 as a white crystalline solid (159 mg, 0.42 mmol, 76%). Crystals precipitated spontaneously during column chromatography. X-ray quality crystals could be grown in a diffusion chamber from hexanes and CHCl3. mp = 104–106°C; TLC Rf = 0.36 (15% EtOAc/PE); [α]D18=+8.7 (c=0.03 CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 0.82 (d, J=6.5 Hz, 3 H), 1.34 (d, J=6.9 Hz, 3 H), 1.69 – 1.78 (m, 1 H), 1.79 – 1.89 (m, 1 H), 1.90 – 1.98 (m, 1 H), 2.22 (d, J=2.4 Hz, 1 H), 2.42 (s, 3 H), 2.53 (dd, J=14.0, 11.4 Hz, 1 H), 2.73 – 2.87 (m, 1 H), 3.55 (dd, J=14.0, 4.00 Hz, 1 H), 4.33 (d, J=10.4 Hz, 1 H), 4.93 – 5.01 (m, 1 H), 7.23 – 7.34 (m, 2 H), 7.79 – 7.90 (m, 2 H). 13C NMR (101 MHz, CDCl3) δ ppm (up) 143.14, 137.53, 84.87, 71.74, 46.77, 36.18; (down) 129.05, 127.87, 63.33, 49.12, 26.80, 24.31, 21.50, 18.42, 18.06; IR (film) 2954, 2871, 1737, 1453, 1336, 1169 cm−1; HRMS calcd for C17H23NO2SBr 384.0633, obsd 384.0631.

(1R,2R)-2-Methyl-1-((2R,4S)-4-methyl-1-tosylpyrrolidin-2-yl)but-3-yn-1-ol (19)

KH(P) (240 mg, 3.0 mmol) was suspended in 10 mL toluene and brought to 60°C with stirring. Stirring was ceased and the KH precipitated. Approximately 9 mL of toluene was then removed from the reactor as it cooled to rt. Then 3.0 mL of CH2Cl2 was added and stirring was resumed. To this was added dropwise a solution comprised of bromohydrin 10 (296 mg, 1.0 mmol) and M-Marshall reagent 16 (332 mg, 1.0 mmol) dissolved in 5 mL of CH2Cl2. After 30 min of stirring at rt, the solution was cooled to −78°C and BF3˙OEt2 (125 µL, 1.0 mmol) was added in one portion. After 1 h, 1 mL of saturated aqueous NaHCO3 was added along with 1 ml of saturated aqueous KF. The reaction was allowed to come to rt. Precipitates were filtered and the resulting biphasic solution was extracted with CH2Cl2 (4 × 10 mL). The combined organic fractions were dried (Na2SO4) and evaporated directly to silica gel for chromatography to give 19 initially as an oil (97 mg, 0.30 mmol, 30% yield from 10). X-ray quality crystals were grown in a diffusion chamber from hexanes and CHCl3. TLC Rf = 0.32 (15% EtOAc/PE); 1H NMR (400 MHz, CDCl3) δ ppm 0.70 (d, J=6.7 Hz, 3 H), 1.20 (dt, J=12.6, 8.8 Hz, 1 H), 1.35 (d, J=6.8 Hz, 3 H), 2.04 – 2.11 (m, 1 H), 2.13 (d, J=2.4 Hz, 1 H), 2.25 – 2.43 (m, 3 H), 2.45 (s, 3 H), 2.59 – 2.70 (m, 1 H), 3.62 (dd, J=9.6, 6.5 Hz, 1 H), 3.92 (ddd, J=8.9, 4.2, 2.5 Hz, 1 H), 4.12 (dt, J=9.6, 2.8 Hz, 1 H), 7.34 (d, J=8.1 Hz, 2 H), 7.74 (d, J=8.1 Hz, 2 H); 13C NMR (101 MHz, CDCl3, rotamers) δ ppm (up) 143.8, 132.8, 85.4, 70.1, 57.0, 33.3; (down) 129.6, 128.0, 75.7, 62.6, 31.9, 29.3, 21.6, 18.1, 17.6.

(S)-Benzyl 3-Methyl-3,4-dihydropyridine-1(2H)-carboxylate (18)

(2S)-N-Cbz norcitronellamine 20 (1.36 g, 4.6 mmol) prepared as for 9 was taken up in 100 mL of CH2Cl2. Sudan III (10 mg) was then added as an indicator. The solution was cooled to −78°C and ozone was bubbled through until the red color faded. Methyl sulfide (1 mL) was then added to reduce the ozonides and the mixture was concentrated to an oil. Toluene (100 mL) and 10 mg of pyridinium p-toluenesulfonate were added, and the mixture was subjected to Dean-Stark distillation until 20 mL of distillate was collected. The solution was then cooled and evaporated directly to silica gel for chromatography to give 21 as an oil (465 mg, 2.0 mmol, 44%); TLC Rf = 0.70 (15% EtOAc/PE); [α]D18=+41.7 (c= 0.09 CHCl3); 1H NMR (400 MHz, CDCl3, rotamers) δ ppm 0.94 – 1.02 (m, 3 H), 1.61 – 1.72 (m, 1 H), 1.90 (d, J=3.2 Hz, 1 H), 2.09 (dt, J=17.2, 5.0 Hz, 1 H), 2.84 – 3.02 (m, 1 H), 3.77 – 3.99 (m, 1 H), 4.75 – 5.01 (m, 1 H), 5.17 (s, 2 H), 6.73 – 6.93 (m, 6 H), 7.26 – 7.48 (m, 5 H); 13C NMR (101 MHz, CDCl3, rotamers) δ ppm (up) 153.4, 153.0, 136.2, 67.3, 67.2, 48.4, 48.0, 29.7, 29.5; (down) 128.3, 128.0, 127.8, 124.8, 124.3, 26.8, 26.7, 18.6; IR (film): 2956, 1711, 1655, 1411, 1344 cm−1; HRMS calcd for C14H18NO2 232.1338, obsd 232.1344.

(2S,3R,5S)-Benzyl 2-Allyl-3-hydroxy-5-methylpiperidine-1-carboxylate (23)

Enecarbamate 21 (911 mg, 3.9 mmol) was dissolved in 100 mL of 95% acetone/H2O at RT. Ammonium acetate (20 mg) was added as a catalyst. The solution was cooled to −78°C and N-bromosuccinimide (842 mg, 4.7 mmol) was added in one portion. The yellow solution was allowed to warm to rt over 3h. Sodium bisulfite (1 g) was then added and the acetone was removed via rotary evaporation. Water (20 mL) was added to dissolve solids and the resulting biphasic solution was extracted with CH2Cl2 (3 × 50 mL). The organic extract was dried (Na2SO4) and evaporated directly to silica gel for chromatography to give 22 as an oil (846 mg, 2.4 mmol, 62%); TLC Rf = 0.38 (25% EtOAc/PE); [α]D18=+26.0 (c= 0.075 CHCl3); 1H NMR (400 MHz, CDCl3, rotamers) δ ppm 0.93 (d, J=6.47 Hz, 3 H), 1.87 – 2.05 (m, 2 H), 2.19 (td, J=11.32, 6.63 Hz, 1 H), 4.36 (br s, 1 H), 5.14 (s, 2 H), 5.90 (br s, 1 H), 7.28 – 7.41 (m, 5 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 136.2, 67.6, 34.6; (down) 128.6, 128.2, 128.0, 49.9, 25.0, 18.3; IR (film): 3394, 2956, 1681, 1431, 1343, 1253 cm−1.

KH(P) (1.0 g, 13.6 mmol) was suspended in 20 mL toluene and brought to 60°C with stirring. Stirring was ceased and the KH precipitated. Approximately 19 mL of toluene was removed from the reactor as it cooled to rt. Methylene chloride (10 mL) was added and stirring was resumed. Bromohydrin 22 (1.11 g, 3.4 mmol) was added dropwise as a solution in 10 mL of CH2Cl2. The opaque yellow solution was allowed stirred for an additional 30 min. The solution was then cooled to −78°C. Stirring was increased, and allylmagnesium chloride (4.0 mL, 1.7 M in THF) was added dropwise over 5 min. Upon completion of addition, the cooling bath was removed. The reaction was allowed to come to rt over 45 min, then quenched with 25 mL of saturated aqueous NH4Cl. The aqueous layer was separated and extracted with 3 × 10 mL CH2Cl2. The combined organic extracts were dried (Na2SO4) and chromatographed to give 23 (840 mg, 53% yield from 21); TLC Rf = 0.2 (30% EtOAc/PE); [α]D19=+37.17 (c= 0.035 CHCl3); 1H NMR (400 MHz, CDCl3) δ ppm 0.90 (t, J=6.95 Hz, 1 H), 1.17 (d, J=6.82 Hz, 2 H), 1.21 – 1.39 (m, 1 H), 1.52 (d, J=13.89 Hz, 1 H), 1.73 (d, J=18.95 Hz, 2 H), 1.86 – 2.03 (m, 2 H), 2.22 – 2.47 (m, 2 H), 3.15 (dd, J=13.52, 3.92 Hz, 1 H), 3.77 (d, J=13.39 Hz, 1 H), 3.85 (br s, 1 H), 4.27 (t, J=6.57 Hz, 1 H), 4.99 – 5.26 (m, 4 H), 5.69 – 5.85 (m, 1 H), 7.30 – 7.44 (m, 5 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 156.9, 136.9, 117.5, 67.1, 44.3, 34.7, 33.1 (down) 134.4, 128.4, 127.9, 127.8, 68.7, 57.9, 27.0, 20.4; IR (film): 3426, 2928, 1677, 1430, 1320, 1250 cm−1; HRMS calcd for C17H24NO3 290.1756, obsd 290.1742.

(3αS,6S,7αR)-benzyl 6-Methyl-2-oxo-hexahydrofuro[3,2-β]pyridine-4(2H)-carboxylate (24)

The alcohol 23 (720 mg, 2.5 mmol) was dissolved in 50 mL 95% acetone/H2O solution.17 The solution was cooled to −78°C and ozone was bubbled through until the solution turned blue. The solution was sparged with air until colorless and then 1 mL of methyl sulfide was added. The bulk of the acetone was removed by rotary evaporation, and the residue was partitioned between 20 mL of brine and 100 mL CH2Cl2. The combined organic extracts were dried (Na2SO4) and concentrated to an oil, which was then dissolved in 5 mL of t-BuOH. K2CO3 (552 mg, 4.0 mmol) and I2 (756 mg, 3.0 mmol) were added sequentially and the solution was heated at 60°C overnight under N2. Water (10 mL) was then added along with 0.50 g of sodium bisulfite and the solution was stirred until the iodine color faded. The mixture was extracted with CH2Cl2 (3×25 mL). The combined organic extracts were dried (Na2SO4) and evaporated directly to silica gel for to give the bicyclic lactone 24 as an oil (380 mg, 1.31 mmol, 53% yield from 23. The spectroscopic data (1H, 13C NMR) matched that which was previously published.5b

(3R,3αS,6S,7αR)-Benzyl 3,6-Dimethyl-2-oxo-hexahydrofuro[3,2-β]pyridine-4(2H)-carboxylate (25)

Bicyclic lactone 24 (80 mg, 0.28 mmol) was dissolved in 3.0 mL THF at rt. Triphenylmethane (10 mg) was added as an indicator. In a separate vessel at 0°C, 9.0 mL THF, diisopropyl amine (303 mg, 3.0 mmol) and n-BuLi (1.0 mL, 2.49 M) were combined. The LDA solution was aged 15 min. Meanwhile, the lactone solution was cooled to −78°C, at which point the LDA solution was added dropwise until an olive green color persisted (~ 1 mL). After 30 min, iodomethane (200 µl, 3.2 mmol) was added in one portion and the solution turned yellow. The solution was diluted with water and extracted with CH2Cl2 (3×20 mL). The combined organic extracts were dried (Na2SO4) and evaporated directly to silica gel for chromatography gave 25 as an oil (30 mg, 0.10 mmol, 30% yield from 24). Crystallization was effected in a CH2Cl2/PE diffusion chamber; mp = 105–106°C; TLC Rf = 0.57 (30% EtOAc/PE); 1H NMR (400 MHz, CDCl3) δppm 1.06 (d, J=6.7 Hz, 3 H), 1.22 – 1.31 (m, 4 H), 1.81 – 1.96 (m, 1 H), 2.33 (dt, J=11.1, 3.9 Hz, 1 H), 2.58 (dd, J=13.0, 11.1 Hz, 1 H), 3.19 (dd, J=10.1, 6.7 Hz, 1 H), 3.30 (quin, J=7.2 Hz, 1 H), 4.02 (dd, J=13.0, 4.0 Hz, 1 H), 4.14 (ddd, J=11.9, 10.0, 4.0 Hz, 1 H), 5.15 (s, 2 H), 7.31 – 7.47 (m, 5 H); 13C NMR (101 MHz, CDCl3) δ ppm (up) 177.8, 157.0, 135.7, 67.8, 53.1, 35.6; (down) 128.7, 128.6, 128.5, 128.4, 77.2, 62.1, 41.4, 28.7, 19.1, 9.5.

Supplementary Material

1_si_001
2_si_002
3_si_003
4_si_004
5_si_005
6_si_006
7_si_007

Acknowledgments

We thank John Dykins for high resolution mass spectrometry under the financial support of NSF 054117, Dr. Shi Bai for NMR spectra financially supported by NSF CRIF:MU, CHE 080401, Glenn Yap for X-ray crystallography help and the National Institutes of Health (GM060287) for financial support of this work.

Footnotes

Supporting Information Available: 1H NMR and 13C NMR spectra for all new compounds as well as 50% probability figures and .cif files for compounds 13, 14, 17, 18, 19 and 25 are available free of charge via the internet at http://pubs.acs.org.

References

  • 1.For the isolation and characterization of (−)-veratramine, see: Saito K. Bull. Chem. Soc. Jpn. 1940;15:22–27. Jacobs J, Craig LC. J. Biol. Chem. 1945;160:555–565. Jacobs C, Sato Y. J. Biol. Chem. 1949;181:55–65. Tamm C, Wintersteiner O. J. Am. Chem. Soc. 1952;74:3842–3849. For partial and total syntheses, see: Masamune T, Takasugi M, Murai A, Kobayashi K. J. Am. Chem. Soc. 1967;89:4521–4523. Masamune T, Takasugi M, Murai A. Tetrahedron. 1971;27:3369–3386. Johnson WS, deJongh HAP, Coverdale CE, Scott JW, Burkhardt U. J. Am. Chem. Soc. 1967;89:4523–45244. Kutney JP, Cable J, Gladstone WAF, Hanssen HW, Torupka EJ, Warnock WDC. J. Am. Chem. Soc. 1967;89:4521–4523. doi: 10.1021/ja01021a083.
  • 2.For references regarding the elucidation of Hh and its implication in various carcinomas, see: Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Nature. 2000;406:1005–1009. doi: 10.1038/35023008. Taipale J, Beachy PA. Nature. 2001;411:349–354. doi: 10.1038/35077219. di Magliano MP, Hebrok M. Nat. Rev. Cancer. 2003;3:903–911. doi: 10.1038/nrc1229. Rubin LL, de Sauvage FJ. Nat. Rev. Drug Discovery. 2006;5:1026–1033. doi: 10.1038/nrd2086. Yauch RL, Gould SE, Scales SG, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, Nannini-Pepe M, Kotkow K, Marsters JC, Jr, Rubin LL, de Sauvage FJ. Nature. 2008;455:406–410. doi: 10.1038/nature07275. Kumar SK, Roy I, Anchoori RK, Fazli S, Maitra A, Beachy PA, Khan SR. Bioorg. Med. Chem. 2008;16:2764–2768. doi: 10.1016/j.bmc.2008.01.012. Zhang J, Garrossian M, Gardner D, Garrossian A, Chang YT, Kim YK, Chang CW. Bioorg.& Med. Chem. Lett. 2008;18:1359–1363. doi: 10.1016/j.bmcl.2008.01.017. Scales SJ, Sauvage FJ. Trends Pharmacol. Sci. 2009;30:303–312. doi: 10.1016/j.tips.2009.03.007. Dlugosz AA, Talpaz M. N. Engl. J. Med. 2009;361:1202–1205. doi: 10.1056/NEJMe0906092. Yang L, Xie G, Fan Q, Xie J. Oncogene. 2009;29:469–481. doi: 10.1038/onc.2009.392. Teglund S, Toftgård R. Biochim. Biophys. Acta. 2010;1805:181–208. doi: 10.1016/j.bbcan.2010.01.003. Hidalgo M, Maitra A. N. Engl. J. Med. 2009;361:2094–2096. doi: 10.1056/NEJMcibr0905857. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, VanArsdale T, Beachy PA, Reya T. Nature. 2009;458:776–779. doi: 10.1038/nature07737.
  • 3.Infinity Pharmaceuticals corporate website. [accessed July 6, 2011]; http://www.infi.com/product-candidates-pipeline-ipi-926.asp.
  • 4.Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC, Yu Y-C, Behnke ML, Nair SJ, Hagel M, White K, Conley J, Manna JD, Alvarez-Diez TM, Hoyt J, Woodward CN, Sydor JR, Pink M, MacDougall J, Campbell MJ, Cushing J, Ferguson J, Curtis MS, McGovern K, Read MA, Palombella VJ, Adams J, Castro AC. J. Med. Chem. 2009;52:4400–4418. doi: 10.1021/jm900305z. [DOI] [PubMed] [Google Scholar]
  • 5.(a) Giannis A, Heretsch P, Sarli V, Stößel A. Angew. Chem. Int. Ed. 2009;48:7911–7914. doi: 10.1002/anie.200902520. [DOI] [PubMed] [Google Scholar]; (b) Heretsch P, Rabe S, Giannis A. Org. Lett. 2009;11:5410–5412. doi: 10.1021/ol902270f. [DOI] [PubMed] [Google Scholar]; (c) Heretsch P, Büttner A, Tzagkaroulaki L, Zahn S, Kirchner B, Giannis A. Chem. Commun. 2011;47:7362–7364. doi: 10.1039/c1cc11782c. [DOI] [PubMed] [Google Scholar]
  • 6.Taber DF, You KK. J. Org. Chem. 1995;117:5757–5762. [Google Scholar]
  • 7.He W, Pinard E, Paquette LA. Helv. Chim. Act. 1995;78:391–402. [Google Scholar]
  • 8.Verardo G, Bombardella E, Geatti P, Strazzolini P. Synthesis. 2008;3:438–444. [Google Scholar]
  • 9.Taber DF, Nelson CG. J. Org. Chem. 2006;71:8973–8974. doi: 10.1021/jo061420v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Huang H, Nelson CG, Taber DF. Tetrahedron Lett. 2010;51:3545–3546. [Google Scholar]
  • 11.(a) Yang D, Zhang C. J. Org. Chem. 2001;66:4814–4818. doi: 10.1021/jo010122p. [DOI] [PubMed] [Google Scholar]; (b) Albert BJ, Sivaramakrishnan A, Naka T, Czaicki NL, Koide K. J. Am. Chem. Soc. 2007;129:2648–5269. doi: 10.1021/ja067870m. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.For Lewis acid-mediated addition to α-substituted cyclic hemiacetals in CH2Cl2: Pirrung MC, Kenney PM. J. Org. Chem. 1987;52:2335–2336. Holmes CP, Bartlett PA. J. Org. Chem. 1989;54:98–108. Takacs JM, Weidner JJ, Newsome PW, Takacs BE, Chidambaram R, Shoemaker R. J. Org. Chem. 1995;60:3473–3486. Pu Y, Ziffer H. J. Med. Chem. 1995;38:613–616. doi: 10.1021/jm00004a007. Maeda K, Shinokubo H, Oshima K. J. Org. Chem. 1997;62:6429–6431. Li W, Mead KT, Smith LT. Tet. Lett. 2003;44:6351–6353. Hodgson R, Nelson A. Org. & Biomol. Chem. 2004;2:373–286. doi: 10.1039/b307950c. Liu Y, Wong V, Ko B, Wong M, Che C. Org. Lett. 2005;7:1561–1564. doi: 10.1021/ol050230o. Lucero CG, Woerpel KA. J. Org. Chem. 2006;71:2641–2647. doi: 10.1021/jo0522963. Singh V, Sarang P, Bhalerao P, Mobin SM. Synlett. 2011;3:386–390.
  • 13.For Lewis acid-mediated addition to α-substituted cyclic hemiaminals in CH2Cl2: Sisko J, Weinreb SM. J. Org. Chem. 1991;56:3210–3211. Johnson CR, Golebiowski A, Sundram H, Miller MW, Dwaihy RL. Tetrahedron Lett. 1995;36:653–654. Adelbrecht J, Craig D, Dymock BW, Thorimbert S. Synlett. 2000:467–470. Ungureanu I, Klotz P, Schoenfelder A, Mann A. Tetrahedron Lett. 2001;42:6087–6091. Harris JM, Padwa A. Org. Lett. 2002;4:2029–2031. doi: 10.1021/ol025859v. Huang P, Wei B, Ruan Y. Synlett. 2003:1663–1667. Chen B, Tasi M, Yang C, Chang J, Chang N. Tetrahedron. 2004;60:10223–10231. Ng PY, Masse CE, Shaw JT. Org. Lett. 2006;8:3999–4002. doi: 10.1021/ol061473z. Blakemore PR, Norcross NR, Warriner SL, Astles PC. Heterocycles. 2006;70:609–617. Norcross NR, Melbardis JP, Solera MR, Sephton MA, Kilner C, Zakharov LN, Astles PC, Warriner SL, Blakemore PR. J. Org. Chem. 2008;73:7939–7951. doi: 10.1021/jo8013512. Kavanagh Y, Chaney CM, Muldoon J, Evans P. J. Org. Chem. 2008;73:8601–8604. doi: 10.1021/jo8017439. Amat M, Perez M, Minaglia AT, Passarella D, Bosch J. Tetrahedron: Asymmetry. 2008;19:2406–2410. Liu R, Huang W, Ma J, Wei B, Lin G. Tetrahedron Lett. 2009;50:4046–4049. Rouchaud A, Braekman J. Eur. J. Org. Chem. 2011;12:2346–2353.
  • 14.(a) Marshall JA, Wang XJ. J. Org. Chem. 1991;56:3211–3213. [Google Scholar]; (b) Marshall JA, Chobanian H. Org. Syn. 2005;82:43–50. [Google Scholar]
  • 15.For the application of Marshall reagent to polyketide synthesis, see: Marshall JA, Johns BA. J. Org. Chem. 1998;63:7885–7892. doi: 10.1021/jo971900+. Marshall JA, Fitzgerald RN. J. Org. Chem. 1999;64:4477–4481. Marshall JA, Johns BA. J. Org. Chem. 2000;65:1501–1510. doi: 10.1021/jo991689x. Marshall JA, Adams ND. Org. Lett. 2000;2:2897–2900. doi: 10.1021/ol006344b. Marshall JA, Yanik MM. J. Org. Chem. 2001;66:1373–1379. doi: 10.1021/jo0056951. Marshall JA, Schaaf GM. J. Org. Chem. 2001;66:7825–7831. doi: 10.1021/jo015936k. Marshall JA, Adams ND. J. Org. Chem. 2002;67:733–740. doi: 10.1021/jo015864x. Marshall JA, Bourbeau MP. Org. Lett. 2002;4:3931–3934. doi: 10.1021/ol026791m.
  • 16.(a) Kotake M, Kawasaki I, Okamoto T, Kusumoto S, Kaneko T. Liebigs Ann. 1960;636:158–164. [Google Scholar]; (b) Arata Y, Nakanishi T, Asaoka Y. Chem. Pharm. Bull. 1962;10:675–679. doi: 10.1248/cpb.10.675. [DOI] [PubMed] [Google Scholar]; (c) Arata Y. JP39-021855.B. Japanese Patent. 1964; (d) Hwang YC, Fowler FW. J. Org. Chem. 1985;50:2719–2726. [Google Scholar]; (e) Hwang YC, Chu M, Fowler FW. J. Org. Chem. 1985;50:3885–3890. [Google Scholar]; (f) Moran WJ, Goodenough KM, Raubo P, Harrity JPA. Org. Lett. 2003;5:3427–3429. doi: 10.1021/ol035156t. [DOI] [PubMed] [Google Scholar]; (g) Goodenough KM, Moran WJ, Raubo P, Harrity JPA. J. Org. Chem. 2005;70:207–213. doi: 10.1021/jo048455k. [DOI] [PubMed] [Google Scholar]; (h) Katoh M, Mizutani H, Honda T. Tetrahedron Lett. 2005;46:5161–5163. [Google Scholar]; (i) Katoh M, Mizutani H, Honda T. Heterocycles. 2006;69:193–216. [Google Scholar]
  • 17.Schiaffo CE, Dussault PH. J. Org. Chem. 2008;73:4688–4690. doi: 10.1021/jo800323x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1_si_001
2_si_002
3_si_003
4_si_004
5_si_005
6_si_006
7_si_007

RESOURCES